Market Overview

Going To The Big Show: Former Pink-Sheet Neurotrope's First Day On The Nasdaq

Going To The Big Show: Former Pink-Sheet Neurotrope's First Day On The Nasdaq

A biotech company making a jump from the OTC market to the Nasdaq is certainly not as difficult as finding a cure for Alzheimer’s Disease. However, OTC investors are well aware that up-listings are a rare phenomenon.

Neurotrope Inc (NASDAQ: NTRP) investors are hoping that the company’s move from the OTC market to the Nasdaq this week is a sign that Neurotrope can beat the odds when it comes to treating Alzheimer’s as well.

“We continue to execute on our clinical and corporate strategy and anticipate announcing top line efficacy results from our randomized, placebo controlled Phase 2 study in 148 moderate to severe Alzheimer’s dementia patients in April 2017,” president and chief scientific officer Daniel Alkon, M.D., said in a press release this week. “We are pleased that we will be able to make that announcement as a NASDAQ listed company.”

Benzinga had the chance to speak with Neurotrope CEO Susanne Wilke, Ph.D., back in January. Wilke discussed the incredible potential the company sees in its Bryostatin drug.

Chatting With Neurotrope's CEO

Although Neurotrope is still a long way from proving its hypothesis, Wilke told Benzinga that Bryostatin may be able to help Alzheimer’s patients reactivate synaptic networks in their brain that have been lost to dementia.

"We believe that this mechanism is a fundamental mechanism for neurodegenerative diseases in general,” Wilke explained. “We definitely want to go into Fragile X [syndrome], we are thinking about Rett Syndrome. There's other areas. Obviously, stroke, Parkinson's, depression may be an area."

Neurotrope stock is off to a great start to 2017, up more than 146 percent year-to-date. The stock had a smooth transition to the Nasdaq on Wednesday, gaining 2.4 percent in its first day of trading on the big board.

Related Link:

Neurotrope: A Company You Never Heard Of Might Have The Biggest Drug Ever In Biotech

Alzheimer's Pipeline In Focus At Oppenheimer Conference As Neurotrope's Trial Results Approach
Image Credit: By User:SElefant - Own work, CC BY-SA 3.0, via Wikimedia Commons

Posted-In: Biotech News Health Care Exclusives Markets Movers Interview General Best of Benzinga


Related Articles (NTRP)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Akamai Technologies Breaches Lower-End Of 33-Day Trading Range

Analysts Respond To Lululemon's Q4 Beat, Weak Outlook